Testing the Safety of EYC-0305 Eye Injections in Wet Age-Related Macular Degeneration
Tests the safety of EYC-0305 eye injections in people with wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Key facts
- Where
- Bellaire, Beverly Hills, Erie, McAllen, Modesto, The Woodlands, and Wake Forest, United StatesSee the 7 sites
- Phase
- Phase 1/2
Where in United States
- Bellaire, TXBellaire, United StatesTaking people
- Beverly Hills, CABeverly Hills, United StatesTaking people
- Erie, PAErie, United StatesTaking people
- McAllen, TXMcAllen, United StatesTaking people
- Modesto, CAModesto, United StatesTaking people
- The Woodlands, TXThe Woodlands, United StatesTaking people
- Wake Forest, NCWake Forest, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eyconis INC.
- Trial code
- NCT07587515
- Record updated
- 9 October 2026
- Original description
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.Read full original descriptionShow less
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Inclusion: Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria; Willing and able to comply with clinic visits and study-related procedures; Provide signed informed consent.
Exclusion: Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion; Known hypersensitivity or known allergy that would preclude study drug administration; Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access; Uncontrolled diabetes mellitus; History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit; Renal failure, dialysis, or history of renal transplant; Pregnant or breastfeeding women.